Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
Condition(s):Secondary HyperparathyroidismLast Updated:April 13, 2017Terminated
Hide Studies Not Open or Pending
Condition(s):Secondary HyperparathyroidismLast Updated:April 13, 2017Terminated
Condition(s):X-linked HypophosphatemiaLast Updated:February 17, 2021Completed
Condition(s):Oncogenic Osteomalacia; Mesenchymal TumorLast Updated:April 7, 2017Unknown status
Condition(s):Primary Hypophosphatemic RicketsLast Updated:October 1, 2013Completed
Condition(s):Hypophosphatemia, Familial; Rickets; HyperphosphatemiaLast Updated:August 31, 2016Unknown status
Condition(s):Secondary HyperparathyroidismLast Updated:April 11, 2017Completed
Condition(s):X-linked HypophosphatemiaLast Updated:October 26, 2020Completed
Condition(s):Familial Hypophosphatemic RicketsLast Updated:December 17, 2020Withdrawn
Condition(s):Renal OsteodystrophyLast Updated:May 5, 2017Completed
Condition(s):X-linked HypophosphatemiaLast Updated:October 21, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.